European Companies Search Engine
EU funding (€2,626,200): European Training Program to Understand, Diagnose and Treat Autosomal Dominant Retinal Diseases Hor11 Jul 2023 EU Research and Innovation programme "Horizon"
Overview
Text
European Training Program to Understand, Diagnose and Treat Autosomal Dominant Retinal Diseases
ProgRET will create a multidisciplinary and intersectoral European training network focusing on the mechanisms, diagnosis and therapy of dominantly inherited retinal diseases (IRD). IRD represent a major cause of blindness, affecting 350,000 people in Europe. IRD have long been considered incurable, however major advances have led to groundbreaking new treatments. Today, the most important challenges in the IRD field relate to an unsolved genetic diagnosis, unknown disease mechanisms and gene therapy development for autosomal dominant IRD (adIRD), representing 25–40% of all IRD cases. We have demonstrated an emerging role for splicing factors, structural variants and non-coding defects in patients with adIRD, and developed novel disease models and gene therapies for adIRD. ProgRET aims to dissect adIRD mechanisms using retinal stem cell and aquatic animal models, to advance adIRD diagnostics using a single-molecule multi-omics framework, and to develop innovative treatments based on RNA therapy and CRISPR-genome editing. These challenges will be tackled by integrating unique expertise and cutting-edge technology within ProgRET, including (multi-)omics, bioinformatics, functional genomics, RNA biology, gene regulation, stem cell technology, retinal organoids, animal models, genome editing and gene therapy. ProgRET will give Doctoral Candidates (DCs) unparalleled training opportunities in outstanding academic and industrial settings through training-by-research via individual research projects, secondments, and network-wide training sessions. All individual training and research activities will provide each DC with the necessary skills in academic and industrial research. ProgRET will make a career in both sectors attractive and improve their career prospects. Finally, our multidisciplinary network offers a unique opportunity to accelerate the understanding, diagnostics and therapeutics for adIRD in Europe, and to translate research findings to healthcare and society.
Funded Companies:
| Company name | Funding amount |
| Fighting Blindness | ? |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | €251,971 |
| Eberhard Karls Universitaet Tuebingen | €260,539 |
| Evotec International GmbH | €260,539 |
| Fondazione Telethon ETS | €259,438 |
| Institut National de la Sante et de la Recherche Medicale | €282,694 |
| Stichting Radboud Universitair Medisch Centrum | €548,741 |
| Universiteit Gent | €525,240 |
| Ustav Molekularni Genetiky AV CR V.V.I. | €237,038 |
Source: https://cordis.europa.eu/project/id/101120562
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Fighting Blindness, Dublin, Ireland.
